The European Patent Office has granted patent No.1,793,809 to SCOLR Pharma's oral modified release ibuprofen formulation.
The oral modified release ibuprofen formulation is based on the company's CDT controlled delivery technology platform, designed for the programmed release of active pharmaceutical ingredients and nutritional products.
The European patent covers the company's approach for optimizing the release profile of ibuprofen, in order to achieve particular blood level concentrations of the active ingredient for a therapeutic purpose.
SCOLR president and CEO Stephen Turner said the grant of the patent expands the company's ibuprofen-related intellectual property portfolio while providing potential value to the product for its future partners.
"Although our business and available resources are focused on growing our nutritional products business into a sustainable source of revenue, we believe that this patent enhances the global market opportunity for our 12-hour ibuprofen formulation and we intend to continue to seek appropriate partnership opportunities for the commercialization of the product," Turner added.
